Health · Pharma & Biotech · 23 hrs ago

Strand plans overseas expansion for blood-based cancer screening test

Strand plans overseas expansion for blood-based cancer screening test

Strand Life Sciences plans to expand CancerSpot overseas, targeting the US, Southeast Asia and West Asia.

The blood-based test looks for DNA patterns that may be linked to cancer, using genome sequencing, DNA analysis and artificial intelligence.

The company is seeking US FDA approval, and expects a key step in that process around February or March next year; it says the US would be its next export market after approval.

CancerSpot is a screening test, not a diagnosis, so a positive result needs further tests such as imaging, endoscopy or a biopsy.

In a study across 43 Indian hospitals, it detected 72 per cent of cancers, including around 65 to 70 per cent at early stages, and had a 1.4 per cent false-positive rate in an independent group.

Strand says the test is meant to complement established screening, including mammography and colonoscopy, and may cover cancers with limited routine screening options.

Strand aims to reduce the India price below ₹10,000 over the next few years; it currently costs up to ₹25,000, and the company has not given a timeline for any further price reduction.

1 source

Related

What people are saying

Dr Ramesh HariharanCEO of Strand Life Sciences
In most regions of the world, one doesn't need it (regulatory approval to operate). Our aspiration is global. There is good opportunity in Southeast Asia, West Asia and other parts of the world, which we will be aggressively pursuing,
via Business Standard